SuO-Val-Cit-PAB-MMAE

• CAT Number: I013750
• Molecular Formula: C₆₃H₉₇N₁₁O₁₆
• Molecular Weight: 1264.51
• Purity: ≥95%
• Target: Drug-Linker Conjugates for ADC
• Solubility: DMSO: 10 mM
• IUPAC Name: [4-[[(2S)-5-(carbamoylamino)-2-[[(2S)-2-[(2,5-dioxopyrrolidin-1-yl)oxycarbonylamino]-3-methylbutanoyl]amino]pentanoyl]amino]phenyl]methyl N-[(2S)-1-[[(2S)-1-[[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]-N-methylcarbamate
• InChI: InChI=1S/C63H97N11O16/c1-15-38(8)53(46(87-13)33-49(77)73-32-20-24-45(73)55(88-14)39(9)56(79)66-40(10)54(78)42-21-17-16-18-22-42)71(11)60(83)51(36(4)5)69-59(82)52(37(6)7)72(12)63(86)89-34-41-25-27-43(28-26-41)67-57(80)44(23-19-31-65-61(64)84)68-58(81)50(35(2)3)70-62(85)90-74-47(75)29-30-48(74)76/h16-18,21-22,25-28,35-40,44-46,50-55,78H,15,19-20,23-24,29-34H2,1-14H3,(H,66,79)(H,67,80)(H,68,81)(H,69,82)(H,70,85)(H3,64,65,84)/t38-,39+,40+,44-,45-,46+,50-,51-,52-,53-,54+,55+/m0/s1
• InChIKey: CIQIZABZFKYHOV-ZUYLRLFMSA-N
• SMILES: CCC(C)C(C(CC(=O)N1CCCC1C(C(C)C(=O)NC(C)C(C2=CC=CC=C2)O)OC)OC)N(C)C(=O)C(C(C)C)NC(=O)C(C(C)C)N(C)C(=O)OCC3=CC=C(C=C3)NC(=O)C(CCCNC(=O)N)NC(=O)C(C(C)C)NC(=O)ON4C(=O)CCC4=O

SuO-Val-Cit-PAB-MMAE(CAT: I013750) is a complex conjugate used in targeted cancer therapies, particularly in the development of antibody-drug conjugates (ADCs). This molecule combines a potent cytotoxic agent, monomethyl auristatin E (MMAE), with a linker (Val-Cit-PAB) designed to be cleaved selectively in the tumor microenvironment. The Val-Cit linker is stable in the bloodstream but is specifically cleaved by cathepsin B, an enzyme highly expressed in cancer cells, thereby releasing the active MMAE toxin within the tumor. The SuO (succinamide-octanoic acid) group further stabilizes the linker and enhances the conjugate’s pharmacokinetic properties. This targeted approach allows for the delivery of the cytotoxic agent directly to cancer cells, minimizing damage to healthy tissues and improving the efficacy and safety profile of the treatment.